Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q2 2020 Report applies the latest data to analyze current activities in the life science deal landscape.

In this report you can find an overview and analysis of the following across the biopharma market in the US, Europe, and Asia (Japan and China):

• Key performance indicators for the life science market
• IPO and private financing activity and performance
• Deal activity for strategic partnership and M&A
• A look ahead and our predictions of the future

Key takeaways from Q2 2020

US
Public and private financing activity remains notably robust, as companies seek to take advantage of the open IPO window and positive industry perceptions from investors

EU
Unlike past quarters, there has been a surge in M&A deals and IPO activity; EU biopharma leaders are taking advantage of favorable biotech markets to purchase companies at a discount

Japan
Pharma and biotech companies saw a rapid recovery from the impact of COVID-19 and growth in the Japan stock market in Q2 2020

China
Five biopharma companies went public in Q2, raising $1,540M in total, with Nanjing Legend Bio, a CAR-T cell therapy developer, completed the largest $424M IPO on NASDAQ